Nutritionist Lovneet Batra explained that preserving lean muscle mass during weight loss requires proper timing of protein intake and regular resistance training. She recommended consuming 1.6–2.2 g of protein per kg of body weight daily, spread across meals (especially post-workout), and lifting weights 3–5 times per week. Smart carbohydrate timing around workouts helps fuel performance without excess fat storage. She stressed avoiding extreme calorie deficits and prioritizing sleep and recovery to minimize muscle loss.

Bengaluru-based Pandorum Technologies has developed a liquid cornea product that can repair damaged corneas without surgery. The injectable gel, made from biomaterials, fills corneal defects, promotes tissue regeneration, and restores vision. It has shown promising results in animal studies and early human trials. The innovation addresses the severe shortage of donor corneas in India, where over 10 million people suffer corneal blindness. The product could become a game-changer for corneal blindness treatment.

The patent for semaglutide (active ingredient in Ozempic, Wegovy, Rybelsus) expires on March 20, 2026, in India. Over two dozen generic versions are set to launch soon from companies including Dr Reddy’s, Sun Pharma, and Zydus Lifesciences. Prices could drop 60–70% initially and up to 80–90% long-term, improving access for diabetes and obesity patients. The market for anti-obesity drugs in India is Rs 3,000–3,500 crore and expected to grow eightfold by 2030. Experts call it a game-changer for affordability.

Obesity management in India is shifting toward non-surgical options as bariatric surgery remains expensive and carries risks. Medical solutions include GLP-1 agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), which reduce appetite and promote 15–20% weight loss. Lifestyle interventions—diet, exercise, behavioral therapy, and digital platforms—are increasingly effective when combined with medication. Experts emphasize sustainable habits over quick fixes, with India’s obesity market growing rapidly due to rising diabetes and lifestyle diseases.

Omakase, a Japanese concept meaning "I leave it to you," is transforming Delhi's bar scene. Patrons fill forms with preferences like gin-based, sweet-and-sour drinks, and mixologists create bespoke cocktails, such as vodka infused with amla murabba or Parle-G biscuit flavors. This surprise element, rooted in trust, appeals to those weary of choices, offering personalized experiences at bars like Call Me Ten and PCO. It extends from traditional sushi meals to experimental Indian dining, blending global trends with local tastes in cocktail culture.

A long-term study in the Journal of the American Heart Association finds younger males (starting around age 35) develop cardiovascular disease risk, particularly coronary heart disease, about 7-10 years earlier than females. Analyzing over 5,100 adults tracked for three decades, males reached 5% CVD incidence seven years sooner, driven by heart disease rather than stroke or heart failure. Factors include hormonal differences, visceral fat accumulation, and behavioral patterns like delayed screening. Experts recommend earlier prevention starting in young adulthood with lifestyle changes and regular check-ups to address risks before symptoms appear.

A large UK study published in JAMA Internal Medicine finds that allopurinol and other urate-lowering therapies for gout significantly reduce heart attack and stroke risk when serum urate levels drop below 360 micromol/L (ideally <300 micromol/L). Analyzing nearly 110,000 gout patients, those achieving target levels showed higher five-year survival and fewer major cardiovascular events. Experts attribute benefits to reduced inflammation from dissolved urate crystals. Gout affects 12 million US adults, with risks rising post-flares. The findings reinforce treat-to-target dosing for dual gout and heart protection, though observational data limits causality proof. Long-term adherence is encouraged despite patient reluctance.

Country music star Jelly Roll (Jason DeFord) revealed testosterone replacement therapy (TRT) as a key factor in his weight loss, having low levels equivalent to a preteen boy. Combined with nutrition, exercise, and lifestyle changes, TRT helped him lose significant weight. Experts explain TRT restores levels to 600-900 ng/dl improving energy, metabolism, muscle mass, and fat loss when paired with healthy habits. About 50% of obese men have low testosterone. Benefits include better body composition and motivation; risks involve side effects if levels exceed normal. TRT is not a standalone weight loss drug and requires monitoring. Jelly Roll plans lifelong therapy.

A new study models the growing burden of frailty among adults aged 40+ with virally suppressed HIV in the USA (estimated 522,000 people), projecting significant health and economic impacts. Nearly half are prefrail or frail, with average age 56. Remaining life expectancy is over 20 years, but around 12 spent with prefrailty/frailty and 10 falls per person. National scaled burdens include millions of life-years and QALYs lost, plus billions in healthcare costs from frailty and falls. The study urges systematic identification, prevention, and treatment of prefrailty, frailty, and falls in routine HIV care through assessments, exercise, bone health, and medication reviews to maintain independence and quality of life.

Excess body weight is a key modifiable risk factor for breast cancer in women, especially post-menopause, with research indicating 20-30% higher risk for obese individuals due to higher estrogen production from fat tissue, chronic inflammation, and insulin resistance. Maintaining healthy weight through diet and exercise can reduce this preventable risk by up to 40%. Experts urge awareness, regular screening, and healthy habits to counter rising cases linked to global obesity trends.